Abstract
Nivolumab, an immune checkpoint inhibitor, exerts anti-tumor effects against various types of malignant tumor, whereas all usual care should be taken to its related adverse events including immune-related adverse events (irAEs). Of these events, nivolumab-induced pneumonitis, which infrequently develops but sometimes results in a fatal outcome, requires an early detection and prompt response. The purpose of this study was to understand the pathogenesis of nivolumab-induced pneumonitis, leading to avoiding its onset and increase in severity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
